Form 4: Sutro Biopharma CSO Buys 17,000 Shares

Sutro Biopharma's Chief Scientific Officer, Hans-Peter Gerber, acquired 17,000 shares of common stock at a weighted average price of $0.8004.

Summary

• Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, Inc. (STRO), purchased 17,000 shares of the company's common stock.
• The transaction occurred on October 15, 2025, at a weighted average price of $0.8004 per share.
• The shares were acquired in multiple transactions with prices ranging from $0.7932 to $0.8015.
• Following this acquisition, Mr. Gerber beneficially owns a total of 71,832 shares of Sutro Biopharma common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) trading plan.

Sentiment

Score: 6

Explanation: The direct purchase of shares by a key executive is a positive signal of confidence. While the dollar amount ($13,606) is modest, it represents a direct investment by someone with deep insight into the company's operations and prospects.

Positives

• The Chief Scientific Officer's direct purchase of company stock signals confidence in Sutro Biopharma's future prospects and valuation.
• Insider buying can often be interpreted as a positive indicator by the market, suggesting management believes the stock is undervalued or expects positive developments.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The purchase by Hans-Peter Gerber, Chief Scientific Officer, implicitly signals his confidence in the company's scientific pipeline and strategic direction.

Industry Context

Insider buying, particularly by key executives like a Chief Scientific Officer, is generally viewed as a positive signal in the biotechnology and pharmaceutical sectors, where R&D success and pipeline value are critical drivers. It suggests that those with intimate knowledge of the company's scientific progress and clinical trials see value in the current stock price, potentially differentiating it from competitors facing similar market pressures.

Corporate Governance

Stakeholder Impact

• Shareholders: The insider purchase may instill greater confidence among existing and potential shareholders, suggesting management believes in the company's value.
• Employees: May boost morale and confidence among employees, seeing leadership invest personally in the company's success.

Key Dates

Recommendation

The Chief Scientific Officer's direct purchase of company stock, even if a modest amount, serves as a positive signal of insider confidence. This action suggests that a key executive with deep knowledge of the company's scientific pipeline and strategic direction believes the stock is a worthwhile investment. While not a massive transaction, it's a tangible vote of confidence that could be a factor for investors considering a 'buy' position, especially when combined with other positive indicators for Sutro Biopharma.

Keywords

Sutro Biopharma, STRO, Insider Trading, Form 4, Stock Purchase, Biopharma, Hans-Peter Gerber, Chief Scientific Officer, Equity Acquisition